Loading clinical trials...
Loading clinical trials...
Phase II Study of the Early Use of Docetaxel in Patients With Biochemical Relapse After Primary Therapy for Prostate Cancer and an Incomplete Response to Androgen Deprivation Therapy.
Conditions
Interventions
docetaxel
Locations
2
United States
OHSU Knight Cancer Institute
Portland, Oregon, United States
University Cancer Center at University of Washington Medical Center
Seattle, Washington, United States
Start Date
May 1, 2007
Primary Completion Date
July 1, 2009
Completion Date
July 1, 2009
Last Updated
April 28, 2017
NCT06926283
NCT06844383
NCT06594926
NCT07177937
NCT06487507
NCT05919264
Lead Sponsor
OHSU Knight Cancer Institute
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions